loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X

Information, Expiry & Status of FDA Orange Book Patents covering DSSTox_CID_28986

Client Email Product
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 VANDA PHARMS INC (63)

filter

01 8586610 (7)

02 8652776 (7)

03 8999638 (7)

04 9072742 (7)

05 9074254 (7)

06 9074255 (7)

07 9074256 (7)

08 9138432 (7)

09 9157121 (7)

filter

01 Blank (63)

filter

01 Blank (63)

filter

01 2025-09-30 (7)

02 2027-11-02 (7)

03 2030-04-05 (7)

04 2030-08-31 (7)

05 2030-10-28 (7)

06 2030-12-17 (7)

07 2031-01-16 (7)

08 2031-02-10 (7)

09 2031-12-28 (7)

URL Supplier Web Content
8586610
2027-11-02
U-1625
22192
METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
2
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
8586610
2027-11-02
U-1625
22192
METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
3
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
8586610
2027-11-02
U-1625
22192
METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
1
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
8586610
2027-11-02
U-1625
22192
METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
5
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
8586610
2027-11-02
U-1625
22192
METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
6
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
9074256
2031-02-10
U-1674
22192
DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
1
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
9072742
2031-01-16
U-1674
22192
DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
1
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
9072742
2031-01-16
U-1674
22192
DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
2
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
9074256
2031-02-10
U-1674
22192
DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
3
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
9072742
2031-01-16
U-1674
22192
DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
5
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Post Enquiry
POST ENQUIRY